Sunstone makes a non-revocable commitment to sell all shares in Nuevolution at a price of SEK 32.5 per share to Amgen, corresponding to SEK 332 million
Nuevolution has been part of Sunstone’s portfolio since 2007 and Sunstone has played an active role in developing the company to a stage that has motivated Amgen to make a bid for it. Sunstone is the biggest shareholder (20.7 %) and has participated in all financings and has been represented on Nuevolution’s board of directors for more than 10 years.
During this period Nuevolution has matured from an intriguing startup to a novel discovery platform company, now impacting how small molecules drugs are being developed in the pharmaceutical industry.
Press inquiries should be adressed to: